Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), ISPA-FINBA-Hospital Universitario Central de Asturias HUCA, Universidad de Oviedo, Avenida de Roma, 33011, Oviedo, Asturias, Spain.
Nanomaterials and Nanotechnology Research Center (CINN-CSIC)-Universidad de Oviedo-Principado de Asturias, Avenida de Roma, 33011, Oviedo, Asturias, Spain.
Clin Epigenetics. 2019 May 16;11(1):81. doi: 10.1186/s13148-019-0675-4.
The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective transport and delivery systems. The use of nanoparticles (NPs) in oncology management offers promising advantages in terms of the efficacy of cancer treatments, but it is still unclear how these NPs may be affecting the epigenome such that safe routine use is ensured. In this work, we summarize the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers or epigenetic drugs in precision medicine, and we describe the transport and release systems of the epigenetic drugs that have been developed to date.
纳米技术在医学上的应用已经彻底改变了人类癌症的治疗方法。与治疗癌症的经典药物一样,表观遗传药物在特异性和效率方面已经得到了发展,特别是因为有可能使用更有效的运输和递药系统。纳米粒子(NPs)在肿瘤管理中的应用在提高癌症治疗效果方面具有很大的优势,但目前尚不清楚这些 NPs 如何影响表观基因组,以确保安全常规使用。在这项工作中,我们总结了在人类癌症中发现的表观遗传改变的重要性,这些改变导致了精准医学中生物标志物或表观遗传药物的出现,并描述了迄今为止开发的表观遗传药物的运输和释放系统。